From rapid 72-hour red flag assessments to comprehensive 10-day deep dives — built for PE firms, strategic acquirers, and Big Pharma deal teams.
Choose the depth of analysis that matches your deal stage and timeline.
Rapid assessment covering all four risk pillars. Identify the deal-breakers before committing significant diligence resources to a target.
Full-spectrum analysis with integration risk modeling, expert source interviews, and actionable renegotiation leverage before you sign.
Start with a complimentary demo assessment. We'll run a sample risk profile on a target of your choice — at no cost — so you can evaluate our depth and methodology before committing.
Most clients begin with an RFA to screen a target, then commission a DDD on those that pass initial review.
Request Free Demo →Commission only the pillar most relevant to your concern. Each component is a complete, standalone audit deliverable. Upgrade to a full RFA or DDD at any time — component fees are credited.
IP ownership, regulatory posture, contracts, freedom-to-operate analysis.
$3,750 Get Legal Assessment →Data quality, reproducibility, infrastructure, API stability, provenance.
$3,750 Get Technical Assessment →Burn rate, revenue quality, customer concentration, forensic accounting ratios.
$3,750 Get Financial Assessment →Team turnover, process maturity, vendor concentration, scalability signals.
$3,750 Get Operational Assessment →Managing multiple deals? Our portfolio tiers offer volume pricing with consistent quality across your entire pipeline — Bronze through Gold based on depth required.
Basic risk assessment with a standard report. Ideal for initial pipeline screening across multiple targets before committing to full diligence.
Enhanced analysis with customized recommendations and an executive summary tailored to your investment thesis and portfolio strategy.
Full deep diligence with integration risk modeling and ongoing consultation throughout the deal lifecycle — from LOI to close.
For firms with consistent deal flow in the genomic data sector, our partnership packages deliver maximum coverage at negotiated rates. Available by request.
Covers a full year of high-cadence deal screening and deep diligence — ideal for active PE firms with 3–5 genomic deals per year.
For strategic acquirers and large PE firms running 6–10+ genomic transactions per year requiring full coverage across all deal stages.
Partnership packages are available by request and subject to scheduling availability. Contact us to discuss terms.
The only question is whether you want to know what's hidden before or after you close. Request a consultation — we'll scope the right engagement for your timeline and risk appetite.
Request a Consultation Get Free Demo Assessment